Canaccord lowered the firm’s price target on Biogen (BIIB) to $220 from $265 and keeps a Buy rating on the shares. The firm noted Q1 results beat consensus and they are encouraged by the solid top-line performance, and EPS actually came in higher than had been expected. Execution will remain the key as they expect more focus on growth and the pipeline in 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue